- Major tech companies like Microsoft, Google, Amazon, and OpenAI are heavily investing in and competing within the AI revolution.
- Trump-era tariffs may benefit AI stocks, while Google faces DOJ rulings and secures a default search engine deal with Apple.
- AI stocks are benefiting from the trend of onshoring and tariffs implemented during the Trump era.
- Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.
MaxCyte licensed its platform technology to Adicet Bio, Inc. for cell therapies, amid reports that Trump-era tariffs benefit AI stocks.
2 reports, 2 independent
Updated Aug 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MaxCyte licensed its platform technology to Adicet Bio, Inc. for cell therapies, amid reports that Trump-era tariffs benefit AI stocks.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.Also in this story
- BP-205 pipeline offers future growth potential, and WAKIX revenue drives company financial performance.
- Harmony Biosciences Holdings, Inc. presented company data at a congress held in Lisbon, Portugal, on August 26, 2025.
- Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.
The entities involved
-
MaxCyte (United States)
Biotech company in Rockville, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyMaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announc
- GlobeNewswireMaxCyte Signs Platform License Agreement with Adicet Bio MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited prog